Released Mar 5, 2015, after the close
10-K filed Mar 5, 2015, 64 days after period end · 0001390478-15-000012
Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.20M$3.20M derived+122.5% vs Q4 2013+47.0% vs Q1 2014
Net Income-$7.96M-$7.96M derivedN/M vs Q4 2013N/M vs Q1 2014
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$5,701,000N/M
Operating Cash Flowderived-$10,734,000N/M
Free Cash Flowderived-$10,743,000N/M
Margins · derived
Operating margin-178.4%+309.0 pt vs Q4 2013
Net margin-249.0%+135.1 pt vs Q4 2013
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2014dderived from reported figures | Q4 2013 | Q4 2012 | Q4 2011dderived from reported figures |
|---|---|---|---|---|
| Revenue | $3.20M | $1.44M | $1.44M | — |
| Net Income | -$7.96M | -$5.52M | -$19.68M | $1.59M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR